サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1335852

加齢黄斑変性（AMD）の世界市場規模・シェア・産業動向分析レポート：薬剤タイプ別（アフリベルセプト、ラニビズマブ、その他）、疾患タイプ別（湿潤型、乾性型）、流通チャネル別、地域別展望・予測、2023年～2030年

Global Age Related Macular Degeneration (AMD) Market Size, Share & Industry Trends Analysis Report By Drug Type (Aflibercept, Ranibizumab and Others), By Disease Type (Wet and Dry), By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2030
出版日: | 発行: KBV Research | ページ情報: 英文 242 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
加齢黄斑変性（AMD）の世界市場規模・シェア・産業動向分析レポート：薬剤タイプ別（アフリベルセプト、ラニビズマブ、その他）、疾患タイプ別（湿潤型、乾性型）、流通チャネル別、地域別展望・予測、2023年～2030年
出版日: 2023年07月31日
発行: KBV Research
ページ情報: 英文 242 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

加齢黄斑変性（AMD）市場規模は2030年までに139億米ドルに達し、予測期間中にCAGR 5.4%の市場成長率で上昇すると予測されています。

しかし、ウェットAMD治療薬にはさまざまな弊害があることが、市場の成長を制約しています。網膜血管炎、眼内炎症、血管閉塞の併発、吐き気、嘔吐、90％の症例で視力低下の停止、眼内出血、眼の充血と炎症、視力の永久喪失などの副作用が成長を制限すると予想されます。高血圧や鼻やのどの炎症も蔓延しています。さらに、これらの薬は目に直接注射されるため、潜在的な危険性があります。これらの問題は市場拡大の妨げになる可能性があります。さらに、COVID-19の大流行は、加齢黄斑変性症（AMD）のような慢性疾患の治療や管理を含め、世界の医療制度に大きな影響を及ぼしたため、加齢黄斑変性症（AMD）市場にも悪影響を及ぼしました。パンデミック発生中は診療所の閉鎖やホスピタリティの低下により、多くの人々が基本的な眼科治療やケアを受けることができなかっています。しかし、パンデミックは加齢黄斑変性（AMD）に対する新たな治療法の開発と承認に影響を及ぼし、AMD市場の拡大に悪影響を及ぼしました。

薬剤タイプの展望

薬剤の種類によって、市場はアフリベルセプト、ラニビズマブ、その他に区分されます。2022年には、アフリベルセプト・セグメンテーションが最大の売上シェアで市場を独占しました。このセグメントは、世界的にアフリベルセプトの使用が増加していること、高齢者の間で加齢黄斑変性症（AMD）が増加していることから拡大するとみられます。

疾患タイプ別展望

疾患タイプに基づき、市場はウェット型とドライ型に分類されます。2022年の市場では、ドライセグメントが大きな収益シェアを獲得しました。乾性AMDは黄斑変性症全体の85～90％を占める。ビタミン製剤は、乾性黄斑変性に対する唯一の治療選択肢です。ルミネート、ジムラ、硝子体内ペグセタコプランは、現在臨床試験が行われている最先端の治療法のほんの一部に過ぎないです。これらの候補が受け入れられることで、ドライ型AMD分野の拡大が今後数年で加速する可能性があります。

流通チャネルの展望

流通チャネル別では、病院薬局、小売薬局、オンライン薬局に分類されます。2022年の市場では、オンラインセグメントが顕著な収益シェアを記録しました。同分野の成長の主因は、インターネット利用の増加、ヘルスケアサービスのデジタル化、ハイテクに精通した消費者の世界の増加です。また、利便性を重視する消費者のオンラインショッピングへの欲求も、増加の要因となっています。

地域別展望

地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。アジア太平洋地域は、2022年の市場においてかなりの収益シェアを占めています。アジア太平洋地域では、滲出型AMDの治療薬の販売が非常に少ないです。しかし、この地域ではAMDが非常に普及しており、潜在的な成長市場となっています。APACでは数社が滲出型AMD治療薬のマーケティングや研究にも携わっています。加えて、この地域は世界全体の加齢黄斑変性症例の3分の1以上を占めているため、湿性加齢黄斑変性治療薬の需要は今後数年間で大幅に増加すると予想されます。

目次

第1章 市場範囲と調査手法

  • 市場の定義
  • 目的
  • 市場範囲
  • セグメンテーション
  • 調査手法

第2章 市場の概要

  • 主なハイライト

第3章 市場概要

  • イントロダクション
    • 概要
      • 市場構成とシナリオ
  • 市場に影響を与える主な要因
    • 市場促進要因
    • 市場抑制要因
  • ポーターファイブフォース分析

第4章 加齢黄斑変性症（AMD）市場に導入された戦略

第5章 世界の加齢黄斑変性症（AMD）市場：薬剤の種類別

  • 世界のアフリベルセプト市場：地域別
  • 世界のラニビズマブ市場：地域別
  • 世界のその他の市場：地域別

第6章 世界の加齢黄斑変性症（AMD）市場：疾患タイプ別

  • 世界の生鮮市場：地域別
  • 世界のドライ市場：地域別

第7章 世界の加齢黄斑変性症（AMD）市場：流通チャネル別

  • 世界の病院薬局市場：地域別
  • 世界の小売薬局市場：地域別
  • 世界のオンライン薬局市場：地域別

第8章 世界の加齢黄斑変性症（AMD）市場：地域別

  • 北米
    • 北米の市場：国別
      • 米国
      • カナダ
      • メキシコ
      • その他北米地域
  • 欧州
    • 欧州の市場：国別
      • ドイツ
      • 英国
      • フランス
      • ロシア
      • スペイン
      • イタリア
      • その他欧州地域
  • アジア太平洋
    • アジア太平洋の市場：国別
      • 中国
      • 日本
      • インド
      • 韓国
      • シンガポール
      • マレーシア
      • その他アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ
    • ラテンアメリカ・中東・アフリカの市場：国別
      • ブラジル
      • アルゼンチン
      • アラブ首長国連邦
      • サウジアラビア
      • 南アフリカ
      • ナイジェリア
      • その他ラテンアメリカ・中東・アフリカ地域

第9章 企業プロファイル

  • Biogen, Inc
  • Bayer AG
  • Apellis Pharmaceuticals, Inc
  • Regeneron Pharmaceuticals, Inc
  • F Hoffmann-La Roche Ltd.
  • Ionis Pharmaceuticals, Inc
  • Novartis AG
  • Sanofi SA
  • Coherus Biosciences, Inc
  • Bausch Health Companies, Inc

第10章 加齢黄斑変性症（AMD）市場での勝利は必須

図表

LIST OF TABLES

  • TABLE 1 Global Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 2 Global Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 3 Global Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 4 Global Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 5 Global Aflibercept Market by Region, 2019 - 2022, USD Million
  • TABLE 6 Global Aflibercept Market by Region, 2023 - 2030, USD Million
  • TABLE 7 Global Ranibizumab Market by Region, 2019 - 2022, USD Million
  • TABLE 8 Global Ranibizumab Market by Region, 2023 - 2030, USD Million
  • TABLE 9 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 10 Global Others Market by Region, 2023 - 2030, USD Million
  • TABLE 11 Global Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 12 Global Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 13 Global Wet Market by Region, 2019 - 2022, USD Million
  • TABLE 14 Global Wet Market by Region, 2023 - 2030, USD Million
  • TABLE 15 Global Dry Market by Region, 2019 - 2022, USD Million
  • TABLE 16 Global Dry Market by Region, 2023 - 2030, USD Million
  • TABLE 17 Global Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 18 Global Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 19 Global Hospital Pharmacy Market by Region, 2019 - 2022, USD Million
  • TABLE 20 Global Hospital Pharmacy Market by Region, 2023 - 2030, USD Million
  • TABLE 21 Global Retail Pharmacy Market by Region, 2019 - 2022, USD Million
  • TABLE 22 Global Retail Pharmacy Market by Region, 2023 - 2030, USD Million
  • TABLE 23 Global Online Pharmacy Market by Region, 2019 - 2022, USD Million
  • TABLE 24 Global Online Pharmacy Market by Region, 2023 - 2030, USD Million
  • TABLE 25 Global Age Related Macular Degeneration (AMD) Market by Region, 2019 - 2022, USD Million
  • TABLE 26 Global Age Related Macular Degeneration (AMD) Market by Region, 2023 - 2030, USD Million
  • TABLE 27 North America Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 28 North America Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 29 North America Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 30 North America Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 31 North America Aflibercept Market by Country, 2019 - 2022, USD Million
  • TABLE 32 North America Aflibercept Market by Country, 2023 - 2030, USD Million
  • TABLE 33 North America Ranibizumab Market by Country, 2019 - 2022, USD Million
  • TABLE 34 North America Ranibizumab Market by Country, 2023 - 2030, USD Million
  • TABLE 35 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 36 North America Others Market by Country, 2023 - 2030, USD Million
  • TABLE 37 North America Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 38 North America Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 39 North America Wet Market by Country, 2019 - 2022, USD Million
  • TABLE 40 North America Wet Market by Country, 2023 - 2030, USD Million
  • TABLE 41 North America Dry Market by Country, 2019 - 2022, USD Million
  • TABLE 42 North America Dry Market by Country, 2023 - 2030, USD Million
  • TABLE 43 North America Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 44 North America Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 45 North America Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 46 North America Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 47 North America Retail Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 48 North America Retail Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 49 North America Online Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 50 North America Online Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 51 North America Age Related Macular Degeneration (AMD) Market by Country, 2019 - 2022, USD Million
  • TABLE 52 North America Age Related Macular Degeneration (AMD) Market by Country, 2023 - 2030, USD Million
  • TABLE 53 US Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 54 US Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 55 US Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 56 US Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 57 US Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 58 US Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 59 US Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 60 US Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 61 Canada Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 62 Canada Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 63 Canada Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 64 Canada Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 65 Canada Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 66 Canada Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 67 Canada Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 68 Canada Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 69 Mexico Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 70 Mexico Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 71 Mexico Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 72 Mexico Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 73 Mexico Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 74 Mexico Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 75 Mexico Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 76 Mexico Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 77 Rest of North America Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 78 Rest of North America Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 79 Rest of North America Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 80 Rest of North America Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 81 Rest of North America Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 82 Rest of North America Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 83 Rest of North America Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 84 Rest of North America Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 85 Europe Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 86 Europe Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 87 Europe Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 88 Europe Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 89 Europe Aflibercept Market by Country, 2019 - 2022, USD Million
  • TABLE 90 Europe Aflibercept Market by Country, 2023 - 2030, USD Million
  • TABLE 91 Europe Ranibizumab Market by Country, 2019 - 2022, USD Million
  • TABLE 92 Europe Ranibizumab Market by Country, 2023 - 2030, USD Million
  • TABLE 93 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 94 Europe Others Market by Country, 2023 - 2030, USD Million
  • TABLE 95 Europe Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 96 Europe Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 97 Europe Wet Market by Country, 2019 - 2022, USD Million
  • TABLE 98 Europe Wet Market by Country, 2023 - 2030, USD Million
  • TABLE 99 Europe Dry Market by Country, 2019 - 2022, USD Million
  • TABLE 100 Europe Dry Market by Country, 2023 - 2030, USD Million
  • TABLE 101 Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 102 Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 103 Europe Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 104 Europe Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 105 Europe Retail Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 106 Europe Retail Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 107 Europe Online Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 108 Europe Online Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 109 Europe Age Related Macular Degeneration (AMD) Market by Country, 2019 - 2022, USD Million
  • TABLE 110 Europe Age Related Macular Degeneration (AMD) Market by Country, 2023 - 2030, USD Million
  • TABLE 111 Germany Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 112 Germany Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 113 Germany Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 114 Germany Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 115 Germany Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 116 Germany Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 117 Germany Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 118 Germany Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 119 UK Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 120 UK Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 121 UK Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 122 UK Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 123 UK Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 124 UK Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 125 UK Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 126 UK Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 127 France Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 128 France Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 129 France Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 130 France Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 131 France Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 132 France Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 133 France Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 134 France Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 135 Russia Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 136 Russia Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 137 Russia Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 138 Russia Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 139 Russia Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 140 Russia Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 141 Russia Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 142 Russia Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 143 Spain Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 144 Spain Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 145 Spain Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 146 Spain Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 147 Spain Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 148 Spain Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 149 Spain Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 150 Spain Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 151 Italy Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 152 Italy Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 153 Italy Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 154 Italy Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 155 Italy Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 156 Italy Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 157 Italy Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 158 Italy Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 159 Rest of Europe Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 160 Rest of Europe Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 161 Rest of Europe Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 162 Rest of Europe Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 163 Rest of Europe Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 164 Rest of Europe Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 165 Rest of Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 166 Rest of Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 167 Asia Pacific Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 168 Asia Pacific Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 169 Asia Pacific Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 170 Asia Pacific Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 171 Asia Pacific Aflibercept Market by Country, 2019 - 2022, USD Million
  • TABLE 172 Asia Pacific Aflibercept Market by Country, 2023 - 2030, USD Million
  • TABLE 173 Asia Pacific Ranibizumab Market by Country, 2019 - 2022, USD Million
  • TABLE 174 Asia Pacific Ranibizumab Market by Country, 2023 - 2030, USD Million
  • TABLE 175 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 176 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
  • TABLE 177 Asia Pacific Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 178 Asia Pacific Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 179 Asia Pacific Wet Market by Country, 2019 - 2022, USD Million
  • TABLE 180 Asia Pacific Wet Market by Country, 2023 - 2030, USD Million
  • TABLE 181 Asia Pacific Dry Market by Country, 2019 - 2022, USD Million
  • TABLE 182 Asia Pacific Dry Market by Country, 2023 - 2030, USD Million
  • TABLE 183 Asia Pacific Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 184 Asia Pacific Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 185 Asia Pacific Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 186 Asia Pacific Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 187 Asia Pacific Retail Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 188 Asia Pacific Retail Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 189 Asia Pacific Online Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 190 Asia Pacific Online Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 191 Asia Pacific Age Related Macular Degeneration (AMD) Market by Country, 2019 - 2022, USD Million
  • TABLE 192 Asia Pacific Age Related Macular Degeneration (AMD) Market by Country, 2023 - 2030, USD Million
  • TABLE 193 China Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 194 China Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 195 China Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 196 China Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 197 China Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 198 China Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 199 China Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 200 China Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 201 Japan Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 202 Japan Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 203 Japan Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 204 Japan Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 205 Japan Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 206 Japan Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 207 Japan Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 208 Japan Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 209 India Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 210 India Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 211 India Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 212 India Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 213 India Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 214 India Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 215 India Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 216 India Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 217 South Korea Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 218 South Korea Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 219 South Korea Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 220 South Korea Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 221 South Korea Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 222 South Korea Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 223 South Korea Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 224 South Korea Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 225 Singapore Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 226 Singapore Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 227 Singapore Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 228 Singapore Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 229 Singapore Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 230 Singapore Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 231 Singapore Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 232 Singapore Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 233 Malaysia Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 234 Malaysia Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 235 Malaysia Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 236 Malaysia Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 237 Malaysia Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 238 Malaysia Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 239 Malaysia Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 240 Malaysia Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 241 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 242 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 243 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 244 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 245 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 246 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 247 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 248 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 249 LAMEA Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 250 LAMEA Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 251 LAMEA Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 252 LAMEA Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 253 LAMEA Aflibercept Market by Country, 2019 - 2022, USD Million
  • TABLE 254 LAMEA Aflibercept Market by Country, 2023 - 2030, USD Million
  • TABLE 255 LAMEA Ranibizumab Market by Country, 2019 - 2022, USD Million
  • TABLE 256 LAMEA Ranibizumab Market by Country, 2023 - 2030, USD Million
  • TABLE 257 LAMEA Others Market by Country, 2019 - 2022, USD Million
  • TABLE 258 LAMEA Others Market by Country, 2023 - 2030, USD Million
  • TABLE 259 LAMEA Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 260 LAMEA Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 261 LAMEA Wet Market by Country, 2019 - 2022, USD Million
  • TABLE 262 LAMEA Wet Market by Country, 2023 - 2030, USD Million
  • TABLE 263 LAMEA Dry Market by Country, 2019 - 2022, USD Million
  • TABLE 264 LAMEA Dry Market by Country, 2023 - 2030, USD Million
  • TABLE 265 LAMEA Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 266 LAMEA Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 267 LAMEA Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 268 LAMEA Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 269 LAMEA Retail Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 270 LAMEA Retail Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 271 LAMEA Online Pharmacy Market by Country, 2019 - 2022, USD Million
  • TABLE 272 LAMEA Online Pharmacy Market by Country, 2023 - 2030, USD Million
  • TABLE 273 LAMEA Age Related Macular Degeneration (AMD) Market by Country, 2019 - 2022, USD Million
  • TABLE 274 LAMEA Age Related Macular Degeneration (AMD) Market by Country, 2023 - 2030, USD Million
  • TABLE 275 Brazil Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 276 Brazil Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 277 Brazil Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 278 Brazil Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 279 Brazil Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 280 Brazil Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 281 Brazil Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 282 Brazil Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 283 Argentina Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 284 Argentina Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 285 Argentina Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 286 Argentina Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 287 Argentina Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 288 Argentina Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 289 Argentina Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 290 Argentina Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 291 UAE Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 292 UAE Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 293 UAE Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 294 UAE Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 295 UAE Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 296 UAE Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 297 UAE Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 298 UAE Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 299 Saudi Arabia Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 300 Saudi Arabia Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 301 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 302 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 303 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 304 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 305 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 306 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 307 South Africa Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 308 South Africa Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 309 South Africa Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 310 South Africa Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 311 South Africa Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 312 South Africa Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 313 South Africa Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 314 South Africa Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 315 Nigeria Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 316 Nigeria Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 317 Nigeria Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 318 Nigeria Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 319 Nigeria Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 320 Nigeria Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 321 Nigeria Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 322 Nigeria Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 323 Rest of LAMEA Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
  • TABLE 324 Rest of LAMEA Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
  • TABLE 325 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 326 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
  • TABLE 327 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 328 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
  • TABLE 329 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 330 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 331 Key Information - Biogen, Inc.
  • TABLE 332 Key Information - Bayer AG
  • TABLE 333 Key Information - Apellis Pharmaceuticals, Inc.
  • TABLE 334 Key Information - Regeneron Pharmaceuticals, Inc.
  • TABLE 335 Key Information - F. Hoffmann-La Roche Ltd.
  • TABLE 336 Key information - Ionis Pharmaceuticals, Inc.
  • TABLE 337 Key Information - Novartis AG
  • TABLE 338 Key Information - Sanofi S.A.
  • TABLE 339 Key Information - Coherus Biosciences, Inc.
  • TABLE 340 key information - Bausch Health Companies, Inc.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Global Age Related Macular Degeneration (AMD) Market, 2019 - 2030, USD Million
  • FIG 3 Key Factors Impacting Age Related Macular Degeneration (AMD)Market
  • FIG 4 Porter's Five Forces Analysis - Age Related Macular Degeneration (AMD) Market
  • FIG 5 Global Age Related Macular Degeneration (AMD) Market share by Drug Type, 2022
  • FIG 6 Global Age Related Macular Degeneration (AMD) Market share by Drug Type, 2030
  • FIG 7 Global Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2030, USD Million
  • FIG 8 Global Age Related Macular Degeneration (AMD) Market share by Disease Type, 2022
  • FIG 9 Global Age Related Macular Degeneration (AMD) Market share by Disease Type, 2030
  • FIG 10 Global Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2030, USD Million
  • FIG 11 Global Age Related Macular Degeneration (AMD) Market share by Distribution Channel, 2022
  • FIG 12 Global Age Related Macular Degeneration (AMD) Market share by Distribution Channel, 2030
  • FIG 13 Global Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2030, USD Million
  • FIG 14 Global Age Related Macular Degeneration (AMD) Market share by Region, 2022
  • FIG 15 Global Age Related Macular Degeneration (AMD) Market share by Region, 2030
  • FIG 16 Global Age Related Macular Degeneration (AMD) Market by Region, 2019 - 2030, USD Million
  • FIG 17 Swot Analysis: Biogen, Inc.
  • FIG 18 Swot Analysis: Bayer AG
  • FIG 19 Swot Analysis: Apellis Pharmaceuticals, Inc.
  • FIG 20 Swot Analysis: Regeneron Pharmaceuticals, Inc.
  • FIG 21 Swot Analysis: F. Hoffmann-La Roche Ltd.
  • FIG 22 Swot Analysis: Ionis Pharmaceuticals, Inc.
  • FIG 23 SWOT Analysis: Novartis AG
  • FIG 24 Swot Analysis: Sanofi S.A.
  • FIG 25 Swot Analysis: Coherus Biosciences, Inc.
  • FIG 26 Swot Analysis: Bausch Health Companies, Inc.
目次

The Global Age Related Macular Degeneration (AMD) Market size is expected to reach $13.9 billion by 2030, rising at a market growth of 5.4% CAGR during the forecast period.

The steep rise in per-capita healthcare spending, in addition to the rising public demand for high- quality, inexpensive healthcare services, is driving the growth of healthcare products, therefore, hospital pharmacy would generate more than 55% share of the market by 2030. The increasing number & size of investments invested in the healthcare industry by governments of different nations is one of the primary drivers of the market's growth. The WHO reports that healthcare spending reached a record high of US $9 trillion (about 11% of global GDP) due to substantial increases in healthcare spending by governments at all income levels. In general, rising government health spending largely offsets declining personal spending. Increasing spending in the healthcare industry has led to an increase in market innovations. Some of the factors impacting the market are increase in elderly population, growing awareness of AMD, and Wet AMD drugs' adverse effects.

As it gets worse with time, vision loss in the elderly is a major issue. The two main types of macula deterioration are wet and dry macular degeneration. Both are possibly fatal and require medical care. According to the WHO, there will be 1.4 billion people aged 60 and older by 2050, up from the current 1 billion. The number of individuals 60 and older worldwide will double (to 2.1 billion) by 2050. Some key players are working on vitreous implants and longer-acting anti-VEGFs that enable sustained medication delivery. Additionally, the most frequent cause of permanent vision loss is macular degeneration. To make the public aware of the effects of AMD and the best treatment options, NGOs, optometrist groups, and health agencies run various programs, activities, and campaigns. The National AMD Awareness Month celebrated in February and strives to increase awareness of AMD as the main cause of visual loss, is one such significant initiative. Rising financing for the condition's research and related activities, which also encourage people to have eye exams to improve the likelihood of early identification, is another factor driving the need for macular degeneration drugs.

However, wet AMD medicines' wide range of negative effects constrains the market's growth. Growth is expected to be restricted by side effects such as retinal vasculitis, intraocular inflammation, concomitant vascular occlusion, nausea, vomiting, stopping loss of vision in 90% of cases, bleeding in the eye, redness & irritation of the eye, and individuals losing their vision permanently. High blood pressure and inflammation of the nose and throat are also prevalent. Furthermore, these medications are injected directly into the eye, which carries potential hazards. These issues may hamper market expansion. Moreover, as the COVID-19 pandemic had significant effects on healthcare systems globally, including the treatment and management of chronic diseases like age-related macular degeneration (AMD), it had a negative impact on the age-related degeneration (AMD) market. Due to clinic closures and reduced hospital capacity during the outbreak, many people could not get basic eye care and treatment. However, the pandemic impacted the development and approval of new treatments for age-related macular degeneration (AMD), which has had a negative effect on the expanding AMD market.

Drug Type Outlook

On the basis of drug type, the market is segmented into aflibercept, ranibizumab, and others. In 2022, the aflibercept segment dominated the market with the maximum revenue share. This segment will expand due to the increased use of the medicine Aflibercept globally and the rise in age-related macular degeneration (AMD) among the older population.

Disease Type Outlook

Based on diseases type, the market is classified into wet, and dry. The dry segment garnered a significant revenue share in the market in 2022. Dry AMD causes 85 to 90% of all cases of macular degeneration. Vitamin formulations are the only treatment options for dry macular degeneration. Luminate, Zimura, and intravitreal pegcetacoplan are only a few of the cutting-edge therapeutic approaches for its treatment that are now being tested in clinical settings. Accepting these candidates could accelerate the dry AMD segment's expansion in the upcoming years.

Distribution Channel Outlook

By distribution channel, the market is categorized into hospital pharmacy, retail pharmacy, and online pharmacy. The online segment recorded a remarkable revenue share in the market in 2022. The segment's growth is primarily driven by rising internet usage, the digitization of healthcare services, and an increase in tech-savvy consumers worldwide. Consumers' desire for online shopping, which is increasingly centered on convenience, is also a factor in the increase.

Regional Outlook

Region wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific region covered a considerable revenue share in the market in 2022. The sale of medications for exudative AMD is now very low in APAC because of problems with accessibility and expensive prescriptions. However, AMD is highly prevalent in this region, making it a potentially growing market. A few companies in APAC are also involved in the marketing and research of exudative AMD therapies. In addition, the demand for wet age-related macular degeneration drugs is expected to rise considerably in the coming years due to the region accounting for more than a third of all age-related macular degeneration cases globally.

Strategies deployed in Age Related Macular Degeneration (AMD) Market

Jun-2023: Bausch + Lomb introduced PreserVision AREDS 2 Formula soft gels plus coenzyme Q10 (CoQ10) in the United States. It is the only eye vitamin that combines the precise nutrient formula advised by the National Eye Institute (NEI) to help reduce the risk of moderate to advanced Age-related Macular Degeneration (AMD) progression in AMD patients with CoQ10 to support heart health.

Feb-2023: Apellis Pharmaceuticals received approval from the U.S. Food & Drug Administration (FDA) for SYFOVRE™ (pegcetacoplan injection). This injection is launched for people with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Aug-2022: Coherus BioSciences announced that the U.S. Food and Drug Administration (FDA) approved CIMERLITM (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis® (ranibizumab injection) for all five indications. This product satisfies all of the FDA's strict requirements for the reference product, including those for quality, safety, and efficacy. The anti-VEGF therapeutic class of biologics, which includes CIMERLITM, has revolutionized how retinal patients can keep or regain eyesight.

Jun-2022: Biogen together with Samsung Bioepis Co., Ltd. launched BYOOVIZ™ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i in the United States. The biosimilar has been approved by FDA and it would be utilized for the treatment of macular edema following retinal vein occlusion, neovascular (wet) age-related macular degeneration (AMD), and myopic choroidal neovascularization. This is an affordable treatment option for patients suffering from retinal vascular disorders.

Feb-2022: Novartis completed the acquisition of Gyroscope Therapeutics, a clinical-stage gene therapy company. With this acquisition, Novartis would take another step toward its goal of providing ophthalmic innovation to treat and prevent blindness globally. The acquisition strengthened its current expertise in retinal disorders and gene therapy.

Oct-2020: Novartis took over Vedere Bio, a growing pharmaceutical company. The acquisition strengthened Novartis' dedication to cell and gene therapy and helped Novartis accelerate its efforts to provide revolutionary treatments to a variety of patients with blinding conditions. Additionally, the acquisition increased Novartis' presence in ophthalmology and strengthened its position as a global leader in AAV-based gene therapy.

Oct-2019: Novartis got the U.S. Food and Drug Administration approval for Beovu® (brolucizumab) injection, also known as RTH258. This injection would be utilized in the treatment of wet age-related macular degeneration (AMD). Beovu is the only anti-VEGF licensed by the FDA to provide both better fluid resolution compared to aflibercept and the capacity to keep eligible wet AMD patients on a three-month dosage interval immediately following a three-month loading phase with uncompromised efficacy.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Bayer AG, Apellis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Novartis AG, Sanofi S.A., Coherus Biosciences, Inc. and Bausch Health Companies, Inc.

Scope of the Study

Market Segments covered in the Report:

By Drug Type

  • Aflibercept
  • Ranibizumab
  • Others

By Disease Type

  • Wet
  • Dry

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Biogen, Inc.
  • Bayer AG
  • Apellis Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Ionis Pharmaceuticals, Inc.
  • Novartis AG
  • Sanofi S.A.
  • Coherus Biosciences, Inc.
  • Bausch Health Companies, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Age Related Macular Degeneration (AMD) Market, by Drug Type
    • 1.4.2 Global Age Related Macular Degeneration (AMD) Market, by Disease Type
    • 1.4.3 Global Age Related Macular Degeneration (AMD) Market, by Distribution Channel
    • 1.4.4 Global Age Related Macular Degeneration (AMD) Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market at a Glance

  • 2.1 Key Highlights

Chapter 3. Market Overview

  • 3.1 Introduction
    • 3.1.1 Overview
      • 3.1.1.1 Market Composition and Scenario
  • 3.2 Key Factors Impacting the Market
    • 3.2.1 Market Drivers
    • 3.2.2 Market Restraints
  • 3.3 Porter Five Forces Analysis

Chapter 4. Strategies deployed in Age Related Macular Degeneration (AMD) Market

Chapter 5. Global Age Related Macular Degeneration (AMD) Market by Drug Type

  • 5.1 Global Aflibercept Market by Region
  • 5.2 Global Ranibizumab Market by Region
  • 5.3 Global Others Market by Region

Chapter 6. Global Age Related Macular Degeneration (AMD) Market by Disease Type

  • 6.1 Global Wet Market by Region
  • 6.2 Global Dry Market by Region

Chapter 7. Global Age Related Macular Degeneration (AMD) Market by Distribution Channel

  • 7.1 Global Hospital Pharmacy Market by Region
  • 7.2 Global Retail Pharmacy Market by Region
  • 7.3 Global Online Pharmacy Market by Region

Chapter 8. Global Age Related Macular Degeneration (AMD) Market by Region

  • 8.1 North America Age Related Macular Degeneration (AMD) Market
    • 8.1.1 North America Age Related Macular Degeneration (AMD) Market by Drug Type
      • 8.1.1.1 North America Aflibercept Market by Country
      • 8.1.1.2 North America Ranibizumab Market by Country
      • 8.1.1.3 North America Others Market by Country
    • 8.1.2 North America Age Related Macular Degeneration (AMD) Market by Disease Type
      • 8.1.2.1 North America Wet Market by Country
      • 8.1.2.2 North America Dry Market by Country
    • 8.1.3 North America Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.1.3.1 North America Hospital Pharmacy Market by Country
      • 8.1.3.2 North America Retail Pharmacy Market by Country
      • 8.1.3.3 North America Online Pharmacy Market by Country
    • 8.1.4 North America Age Related Macular Degeneration (AMD) Market by Country
      • 8.1.4.1 US Age Related Macular Degeneration (AMD) Market
        • 8.1.4.1.1 US Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.1.4.1.2 US Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.1.4.1.3 US Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.1.4.2 Canada Age Related Macular Degeneration (AMD) Market
        • 8.1.4.2.1 Canada Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.1.4.2.2 Canada Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.1.4.2.3 Canada Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.1.4.3 Mexico Age Related Macular Degeneration (AMD) Market
        • 8.1.4.3.1 Mexico Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.1.4.3.2 Mexico Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.1.4.3.3 Mexico Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.1.4.4 Rest of North America Age Related Macular Degeneration (AMD) Market
        • 8.1.4.4.1 Rest of North America Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.1.4.4.2 Rest of North America Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.1.4.4.3 Rest of North America Age Related Macular Degeneration (AMD) Market by Distribution Channel
  • 8.2 Europe Age Related Macular Degeneration (AMD) Market
    • 8.2.1 Europe Age Related Macular Degeneration (AMD) Market by Drug Type
      • 8.2.1.1 Europe Aflibercept Market by Country
      • 8.2.1.2 Europe Ranibizumab Market by Country
      • 8.2.1.3 Europe Others Market by Country
    • 8.2.2 Europe Age Related Macular Degeneration (AMD) Market by Disease Type
      • 8.2.2.1 Europe Wet Market by Country
      • 8.2.2.2 Europe Dry Market by Country
    • 8.2.3 Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.2.3.1 Europe Hospital Pharmacy Market by Country
      • 8.2.3.2 Europe Retail Pharmacy Market by Country
      • 8.2.3.3 Europe Online Pharmacy Market by Country
    • 8.2.4 Europe Age Related Macular Degeneration (AMD) Market by Country
      • 8.2.4.1 Germany Age Related Macular Degeneration (AMD) Market
        • 8.2.4.1.1 Germany Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.2.4.1.2 Germany Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.2.4.1.3 Germany Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.2.4.2 UK Age Related Macular Degeneration (AMD) Market
        • 8.2.4.2.1 UK Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.2.4.2.2 UK Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.2.4.2.3 UK Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.2.4.3 France Age Related Macular Degeneration (AMD) Market
        • 8.2.4.3.1 France Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.2.4.3.2 France Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.2.4.3.3 France Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.2.4.4 Russia Age Related Macular Degeneration (AMD) Market
        • 8.2.4.4.1 Russia Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.2.4.4.2 Russia Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.2.4.4.3 Russia Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.2.4.5 Spain Age Related Macular Degeneration (AMD) Market
        • 8.2.4.5.1 Spain Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.2.4.5.2 Spain Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.2.4.5.3 Spain Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.2.4.6 Italy Age Related Macular Degeneration (AMD) Market
        • 8.2.4.6.1 Italy Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.2.4.6.2 Italy Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.2.4.6.3 Italy Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.2.4.7 Rest of Europe Age Related Macular Degeneration (AMD) Market
        • 8.2.4.7.1 Rest of Europe Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.2.4.7.2 Rest of Europe Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.2.4.7.3 Rest of Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel
  • 8.3 Asia Pacific Age Related Macular Degeneration (AMD) Market
    • 8.3.1 Asia Pacific Age Related Macular Degeneration (AMD) Market by Drug Type
      • 8.3.1.1 Asia Pacific Aflibercept Market by Country
      • 8.3.1.2 Asia Pacific Ranibizumab Market by Country
      • 8.3.1.3 Asia Pacific Others Market by Country
    • 8.3.2 Asia Pacific Age Related Macular Degeneration (AMD) Market by Disease Type
      • 8.3.2.1 Asia Pacific Wet Market by Country
      • 8.3.2.2 Asia Pacific Dry Market by Country
    • 8.3.3 Asia Pacific Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.3.3.1 Asia Pacific Hospital Pharmacy Market by Country
      • 8.3.3.2 Asia Pacific Retail Pharmacy Market by Country
      • 8.3.3.3 Asia Pacific Online Pharmacy Market by Country
    • 8.3.4 Asia Pacific Age Related Macular Degeneration (AMD) Market by Country
      • 8.3.4.1 China Age Related Macular Degeneration (AMD) Market
        • 8.3.4.1.1 China Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.3.4.1.2 China Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.3.4.1.3 China Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.3.4.2 Japan Age Related Macular Degeneration (AMD) Market
        • 8.3.4.2.1 Japan Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.3.4.2.2 Japan Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.3.4.2.3 Japan Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.3.4.3 India Age Related Macular Degeneration (AMD) Market
        • 8.3.4.3.1 India Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.3.4.3.2 India Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.3.4.3.3 India Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.3.4.4 South Korea Age Related Macular Degeneration (AMD) Market
        • 8.3.4.4.1 South Korea Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.3.4.4.2 South Korea Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.3.4.4.3 South Korea Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.3.4.5 Singapore Age Related Macular Degeneration (AMD) Market
        • 8.3.4.5.1 Singapore Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.3.4.5.2 Singapore Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.3.4.5.3 Singapore Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.3.4.6 Malaysia Age Related Macular Degeneration (AMD) Market
        • 8.3.4.6.1 Malaysia Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.3.4.6.2 Malaysia Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.3.4.6.3 Malaysia Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.3.4.7 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market
        • 8.3.4.7.1 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.3.4.7.2 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.3.4.7.3 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Distribution Channel
  • 8.4 LAMEA Age Related Macular Degeneration (AMD) Market
    • 8.4.1 LAMEA Age Related Macular Degeneration (AMD) Market by Drug Type
      • 8.4.1.1 LAMEA Aflibercept Market by Country
      • 8.4.1.2 LAMEA Ranibizumab Market by Country
      • 8.4.1.3 LAMEA Others Market by Country
    • 8.4.2 LAMEA Age Related Macular Degeneration (AMD) Market by Disease Type
      • 8.4.2.1 LAMEA Wet Market by Country
      • 8.4.2.2 LAMEA Dry Market by Country
    • 8.4.3 LAMEA Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.4.3.1 LAMEA Hospital Pharmacy Market by Country
      • 8.4.3.2 LAMEA Retail Pharmacy Market by Country
      • 8.4.3.3 LAMEA Online Pharmacy Market by Country
    • 8.4.4 LAMEA Age Related Macular Degeneration (AMD) Market by Country
      • 8.4.4.1 Brazil Age Related Macular Degeneration (AMD) Market
        • 8.4.4.1.1 Brazil Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.4.4.1.2 Brazil Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.4.4.1.3 Brazil Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.4.4.2 Argentina Age Related Macular Degeneration (AMD) Market
        • 8.4.4.2.1 Argentina Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.4.4.2.2 Argentina Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.4.4.2.3 Argentina Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.4.4.3 UAE Age Related Macular Degeneration (AMD) Market
        • 8.4.4.3.1 UAE Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.4.4.3.2 UAE Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.4.4.3.3 UAE Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.4.4.4 Saudi Arabia Age Related Macular Degeneration (AMD) Market
        • 8.4.4.4.1 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.4.4.4.2 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.4.4.4.3 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.4.4.5 South Africa Age Related Macular Degeneration (AMD) Market
        • 8.4.4.5.1 South Africa Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.4.4.5.2 South Africa Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.4.4.5.3 South Africa Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.4.4.6 Nigeria Age Related Macular Degeneration (AMD) Market
        • 8.4.4.6.1 Nigeria Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.4.4.6.2 Nigeria Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.4.4.6.3 Nigeria Age Related Macular Degeneration (AMD) Market by Distribution Channel
      • 8.4.4.7 Rest of LAMEA Age Related Macular Degeneration (AMD) Market
        • 8.4.4.7.1 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Drug Type
        • 8.4.4.7.2 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Disease Type
        • 8.4.4.7.3 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Distribution Channel

Chapter 9. Company Profiles

  • 9.1 Biogen, Inc.
    • 9.1.1 Company Overview
    • 9.1.2 Financial Analysis
    • 9.1.3 Regional Analysis
    • 9.1.4 Research & Development Expense
    • 9.1.5 Recent strategies and developments:
      • 9.1.5.1 Partnerships, Collaborations, and Agreements:
    • 9.1.6 SWOT Analysis
  • 9.2 Bayer AG
    • 9.2.1 Company Overview
    • 9.2.2 Financial Analysis
    • 9.2.3 Segmental and Regional Analysis
    • 9.2.4 Research & Development Expense
    • 9.2.5 SWOT Analysis
  • 9.3 Apellis Pharmaceuticals, Inc.
    • 9.3.1 Company Overview
    • 9.3.2 Financial Analysis
    • 9.3.3 Segmental Analysis
    • 9.3.4 Research & Development Expenses
    • 9.3.5 Recent strategies and developments:
      • 9.3.5.1 Approvals & Trails:
    • 9.3.6 SWOT Analysis
  • 9.4 Regeneron Pharmaceuticals, Inc.
    • 9.4.1 Company Overview
    • 9.4.2 Financial Analysis
    • 9.4.3 Research & Development Expense
    • 9.4.4 SWOT Analysis
  • 9.5 F. Hoffmann-La Roche Ltd.
    • 9.5.1 Company Overview
    • 9.5.2 Financial Analysis
    • 9.5.3 Segmental and Regional Analysis
    • 9.5.4 Research & Development Expense
    • 9.5.5 SWOT Analysis
  • 9.6 Ionis Pharmaceuticals, Inc.
    • 9.6.1 Company Overview
    • 9.6.2 Financial Analysis
    • 9.6.3 Research & Development Expenses
    • 9.6.4 SWOT Analysis
  • 9.7 Novartis AG
    • 9.7.1 Company Overview
    • 9.7.2 Financial Analysis
    • 9.7.3 Segmental and Regional Analysis
    • 9.7.4 Research & Development Expense
    • 9.7.5 Recent strategies and developments:
      • 9.7.5.1 Approvals & Trails:
      • 9.7.5.2 Acquisition and Mergers:
    • 9.7.6 SWOT Analysis
  • 9.8 Sanofi S.A.
    • 9.8.1 Company Overview
    • 9.8.2 Financial Analysis
    • 9.8.3 Segmental and Regional Analysis
    • 9.8.4 Research & Development Expense
    • 9.8.5 SWOT Analysis
  • 9.9 Coherus Biosciences, Inc.
    • 9.9.1 Company Overview
    • 9.9.2 Financial Analysis
    • 9.9.3 Research & Development Expenses
    • 9.9.4 Recent strategies and developments:
      • 9.9.4.1 Approvals & Trials:
    • 9.9.5 SWOT Analysis
  • 9.10. Bausch Health Companies, Inc.
    • 9.10.1 Company Overview
    • 9.10.2 Financial Analysis
    • 9.10.3 Segmental and Regional Analysis
    • 9.10.4 Research & Development Expense
    • 9.10.5 Recent strategies and developments:
      • 9.10.5.1 Product Launches and Product Expansions:
    • 9.10.6 SWOT Analysis

Chapter 10. Winning Imperative for Age Related Macular Degeneration (AMD) Market